Rural patients are excluded from clinical trials primarily because trials are designed around urban and suburban infrastructure—sites are concentrated near academic medical centers, patient populations are sparse and geographically dispersed, and the logistics of bringing rural patients to centralized trial locations becomes prohibitively expensive and time-consuming. A 2021 analysis of Alzheimer’s disease trials found that approximately 80% of trial sites were located within metropolitan areas, even though rural residents make up nearly 20% of the U.S. population and experience dementia at rates comparable to their urban counterparts.
The exclusion is rarely intentional; rather, it reflects the structural reality that recruiting 50 patients in a rural county requires exponentially more time and travel than recruiting them from a dense urban neighborhood with established medical infrastructure. This exclusion has consequences that ripple far beyond research participation. When rural patients are systematically absent from trials, the resulting treatments and interventions are tested primarily on urban populations with different healthcare access, different medication interactions, different rates of comorbid conditions, and different transportation and adherence patterns. A dementia medication that works well for an urban patient with reliable access to specialists may perform differently—or be adopted less successfully—in a rural setting where follow-up visits require four-hour drives and specialists are unavailable.
Table of Contents
- How Geographic Distance Creates a Hard Barrier to Trial Entry
- Limited Trial Site Infrastructure in Rural Communities
- Recruitment Disparities and Awareness Gaps
- Socioeconomic and Healthcare Access Constraints
- Data Collection and Follow-Up Challenges in Sparse Populations
- Provider Participation and Gatekeeping Effects
- Long-Term Impacts on Treatment Disparities
How Geographic Distance Creates a Hard Barrier to Trial Entry
The single largest obstacle is simply distance. Most clinical trials require participants to visit a trial site at baseline, regularly during the study, and at final assessment—often monthly, sometimes weekly. For an urban patient, this might mean a 20-minute bus ride or drive. For a rural patient in Montana, rural Maine, or rural Mississippi, it can mean a 100+ mile round trip, multiple times per month, for 12 to 36 months.
Trial protocols rarely compensate for travel time, fuel, or the wage loss from missed work, and many rural patients cannot absorb those costs. This distance barrier systematically excludes working-age rural adults and rural elderly patients who lack robust transportation networks. An urban patient can use public transit, call a ride-share service, or rely on family to drive them. A rural patient may own a car but depend on it for agricultural work, lack family members nearby to provide regular rides (rural areas have higher rates of adult children relocating to cities), or live too far from public transportation to reach a trial site. A 2020 study of rural dementia patients found that 43% had no reliable transportation to routine medical appointments—and trial visits are more frequent and more rigid than regular clinic visits.
Limited Trial Site Infrastructure in Rural Communities
trial sites are expensive to establish and maintain. They require trained research coordinators, regulatory oversight, and sufficient patient volume to justify the infrastructure investment. Academic medical centers and large urban hospitals can amortize these costs across dozens of trials. A rural hospital in a county with 15,000 residents cannot justify the same investment for a single trial that might recruit 8 to 12 local participants.
The result is geographic inequality in trial availability. According to ClinicalTrials.gov data, a patient in New York City has access to over 3,000 active trials; a patient in rural South Dakota has access to fewer than 50. This isn’t because rural patients lack disease—it’s because rural hospitals and clinics cannot afford the compliance infrastructure, data security systems, and staff training that trials demand. Even well-resourced rural hospitals in areas with larger populations often host only disease-specific trials (cancer, heart disease) and rarely participate in neurodegenerative disease trials, which require specialized cognitive assessments and long-term follow-up.
Recruitment Disparities and Awareness Gaps
Trial recruitment in urban areas often happens through established healthcare systems, patient registries, and disease-specific networks. An Alzheimer’s patient in Boston is likely to hear about a trial through her neurologist, her primary care clinic, or an Alzheimer’s Association chapter meeting. A rural patient may have a primary care physician but no neurology access and minimal disease-specific community infrastructure. Rural areas have fewer support groups, fewer disease-specific nonprofits, and lower rates of specialist consultation—which means lower awareness that trials exist.
Rural patients also face higher rates of undiagnosed or late-diagnosed dementia, which narrows the recruitment window. An urban patient with cognitive concerns can see a neurologist within weeks; a rural patient may wait months or consult only their primary care doctor, who may not recognize early cognitive symptoms that warrant referral. By the time a rural patient is formally diagnosed, they may already be ineligible for early-stage trials that require mild cognitive impairment, not frank dementia. This creates a selection bias: the rural patients who do enter trials tend to be further along in disease progression and may not be representative of the broader rural dementia population.
Socioeconomic and Healthcare Access Constraints
Rural trial participation requires financial flexibility that many rural patients lack. Even if a trial offers transportation reimbursement or meal vouchers, participants must still take time off work or arrange caregiving for family members. Rural areas have lower median incomes, higher rates of part-time and gig work, and fewer jobs with flexible schedules or paid leave. An urban trial participant might be able to negotiate a work-from-home schedule around clinic visits; a rural farmer, small-business owner, or hourly service worker cannot.
Healthcare fragmentation in rural areas also complicates trial participation. Rural patients often see multiple providers in different systems—a primary care doctor in one town, a cardiologist 45 minutes away, a psychiatrist via telemedicine. Trials require integrated medical records, medication reconciliation, and coordination with all of a patient’s providers. In fragmented rural healthcare, this coordination burden falls on the patient, who may not remember all of their medications or understand how a trial medication interacts with other drugs they’re taking. This increases the risk that a rural patient will be screen-failed during trial enrollment for unrevealed drug interactions or uncontrolled comorbidities.
Data Collection and Follow-Up Challenges in Sparse Populations
Clinical trials generate enormous amounts of data—cognitive assessments, blood draws, imaging, medication diaries, caregiver surveys—often on tight schedules. Urban trial sites benefit from centralized labs, imaging centers, and trained staff who handle this work daily. Rural trial sites must improvise: blood samples may need to be shipped overnight to a central lab (adding cost and complexity), imaging may not be available locally (requiring the patient to travel to a distant facility anyway), and cognitive assessments may need to be conducted by primary care staff who are not research-trained.
The risk of lost follow-up is also higher in rural settings. Rural patients move more frequently (agricultural work, economic instability), are harder to track by mail or phone if they change addresses or phone numbers, and may drop out if repeated visits become genuinely impossible. A 2019 rural health study found that 28% of rural trial participants dropped out before study completion, compared to 18% of urban participants, often citing transportation or scheduling conflicts. When rural dropout rates are high, trial data becomes less complete and less reliable, and the trial may undershoot its target enrollment—forcing researchers to recruit additional rural participants (further stretching resources) or abandon rural recruitment altogether.
Provider Participation and Gatekeeping Effects
Most trials depend on referring physicians to identify eligible patients and shepherd them into trials. In urban areas, primary care doctors, specialists, and geriatricians have established relationships with trial coordinators and receive regular information about recruiting trials. In rural areas, this network is absent.
A rural primary care doctor may see 20-30 dementia patients per year but receive no information about dementia trials, has limited time to discuss trial participation during annual visits, and may not know how to screen patients for eligibility or how to connect them with trials. Some rural providers actively discourage trial participation out of concern for patient burden or because they lack experience with research protocols. Others view trials as irrelevant to their practice because no local sites participate. This gatekeeping—intended or not—means that eligible rural patients never learn that trials exist, and researchers never see them as potential participants.
Long-Term Impacts on Treatment Disparities
The exclusion of rural patients from trials has measurable downstream effects. When new Alzheimer’s or Parkinson’s medications are tested primarily on urban, more affluent populations with better healthcare access and higher rates of specialist care, the resulting drugs and dosing regimens may not perform as well in rural settings, where medication adherence is lower, follow-up is sporadic, and comorbidities are often unmanaged. A drug approved based on urban trial data may have an efficacy gap in rural populations—not because the drug is inherently less effective, but because rural patients start at higher disease burden and have fewer resources to support treatment adherence.
This contributes to rural-urban disparities in dementia outcomes. Urban dementia patients have earlier diagnosis, faster access to new treatments, more frequent specialist contact, and better medication adherence—partly because they participated in trials and their doctors learned about new drugs early. Rural dementia patients learn about new treatments months or years later, often through word-of-mouth or during a hospital admission, by which time the medication may no longer be appropriate for their disease stage.
- —
